Drug Database
IN

influenza vaccine

✓ Approved

China National Pharmaceutical · 疫苗 · 疫苗

什么是 influenza vaccine?

influenza vaccine 是一种疫苗,由China National Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

公司China National Pharmaceutical
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

相关研究文献

PubMedNPJ vaccines2026-11-19

Influenza neuraminidase as adjuvanted protein or mRNA vaccine protects mice against influenza A and B virus challenge.

Portela Catani João Paulo JP, Smet Anouk A, Ysenbaert Tine T, Amelinck Laura L et al.

Neuraminidase (NA) is an underutilized influenza vaccine antigen despite its recognized contribution to protective immunity. Here, we compared the immunogenicity and protective potential of multiple NA antigens delivered as an adjuvanted recombinant tetrameric protein or as mRNA-LNP encoding full-length NA in naïve mice. Both vaccine types induced robust neuraminidase-inhibiting (NAI) antibody responses and conferred protection to mice challenged with antigenically homologous influenza A or B viruses. However, only immunization with NA-encoding mRNA-LNP protected against challenge with a heterologous HxN2 virus, whereas immunization with recombinant NA was associated with earlier onset of weight loss following heterologous HxN2 virus challenge. Passive transfer of immune serum revealed that protection induced by mRNA immunization can be transferred by serum, and that early onset of weight loss is not induced by recombinant NA-derived sera; on the contrary, partial protection is achieved. Finally, NAI assays against a panel of antigenically distinct HxN2 viruses showed similar breadth of inhibition.

PMID 43052397
阅读全文 →
PubMedThe Medical journal of Australia2026-11-19

Influenza A(H3N2) Subclade K Activity in Australia in 2025: Epidemiology and Vaccine Effectiveness Results From General Practice Sentinel Surveillance.

Chilver Monique B N MBN, Sullivan Sheena G SG, Selway Caitlin A CA, Miller Jessica E JE et al.

To describe the epidemiology, clinical characteristics, vaccine effectiveness (VE), antiviral prescribing and virological properties for influenza A(H3N2) subclade K detected through Australian general practice sentinel surveillance in 2025. Retrospective, observational study using routinely collected general practice surveillance data; VE was estimated using a test-negative design. Data were collected from sentinel general practice sites participating in Australian Sentinel Practices Research Network surveillance across Australia during International Organization for Standardization weeks 1-52 of 2025. Patients presenting with influenza-like illness were systematically selected for virological sampling. Demographic and clinical characteristics of patients with laboratory-confirmed influenza; VE against general practice-attended, laboratory-confirmed influenza; antiviral prescribing; and sequence-based markers of reduced antiviral susceptibility. Among 3185 patients with influenza-like illness who were swabbed, 666 (21%) tested positive for influenza. Influenza A(H3N2) subclade K was first detected in week 34 of 2025 and circulated beyond the typical influenza season, peaking in November-December. Of 98 subclade K detections, 36 (37%) were in children aged 5-17 years. Compared with other types, subtypes or subclades of influenza, clinical presentations of subclade K cases were broadly similar, with no consistent clinical pattern distinguishing subclade K. VE against subclade K was 50% overall (95% confidence interval, 8.9-73) and 76% among persons aged 9 months to 17 years (95% confidence interval, 18-93). Among all patients with a recorded antiviral prescription, two-thirds were within the recommended 48-h symptom onset window (76/114). No subclade K viruses had mutations known to reduce susceptibility to the influenza antivirals assessed, including oseltamivir. Among patients attending Australian sentinel general practices in 2025, subclade K prolonged influenza activity into the summer months. General practice sentinel surveillance of influenza can provide timely information on emerging variants and changes in the timing of influenza circulation, raising clinical awareness outside the usual season, informing vaccination strategies and prompting assessment for antiviral treatment.

PMID 43053545
阅读全文 →
PubMedAJE advances : research in epidemiology2026-11-19

Can self- or caregiver-administered nasal spray influenza vaccination improve outcomes? An agent-based model using the framework for reconstructing epidemiological dynamics.

Williams Katherine V KV, Nowalk Mary Patricia MP, Krauland Mary G MG, Mandell Alexis J AJ et al.

Newly licensed self- or caregiver-administered nasal spray live attenuated influenza vaccine (LAIV), available to order for home delivery, may improve vaccination coverage (VC) among adults aged 18-49 overall, as well as among those in this age group who live in households with school-aged children. Using the agent-based Framework for Reproducing Epidemiological Dynamics, which simulates influenza transmission in US census-based populations with defined household structures, we modeled the impact of: (1) 5%-15% VC increase among those aged 18-49 through self-administration and (2) household-based strategies for ages 5-17 and 18-49 that may occur from home LAIV orders. The household strategies included vaccinating children aged 5-17, followed by their 18-49-year-old head of household (HH) (kids + HH), and vaccinating children aged 5-17 and all household adults aged 18-49 (kids + adults). A 5%-15% VC increase in adults aged 18-49 reduced symptomatic cases in all adults by up to 10%. Among household strategies, kids + adults yielded a higher VC increase (9.2%) and greater reduction in symptomatic cases (5.7%) among adults ≥18 than the kids + HH strategy. The convenience of self-administration and household-based LAIV strategies in homes with school-age children may enhance adult VC and reduce influenza burden.

PMID 43053808
阅读全文 →
PubMedAJE advances : research in epidemiology2026-11-19

Assessing the broader impact of influenza: a meta-analysis of cause-specific and all-cause influenza-associated mortality.

Wong Jessica Y JY, Cheung Justin K JK, Wu Jiaxin S JS, Choi Sammi S et al.

The mortality impact of influenza epidemics is often quantified via increases in respiratory mortality, but this may not fully capture other health outcomes like cardiovascular events. We aimed to explore the ratios of influenza-associated cause-specific to all-cause mortality. We reviewed relevant articles from PubMed and EMBASE which reported both influenza-associated all-cause mortality and at least 1 death grouping: pneumonia and influenza (P&I), respiratory, or respiratory plus cardiovascular (R + C) diseases. Only population-based estimates from influenza seasons were included. We included 130 mortality ratio estimates from 54 studies. We identified substantial heterogeneity in estimates (0.012-0.93). Higher ratio estimates were attributed to R + C diseases (0.45-0.93) compared with respiratory diseases (0.078-0.66) or P&I (0.012-0.38). Respiratory mortality to all-cause mortality ratios increased substantially with age. Our review quantifies the broader mortality burden of influenza, with substantial impact associated with cardiovascular deaths in addition to influenza-associated respiratory deaths.

PMID 43053809
阅读全文 →
PubMedEmerging infectious diseases2026-11-19

Serologic Evidence of Avian Influenza Virus Exposure in Livestock, Egypt, 2024-2026.

Gomaa Mokhtar M, El-Shesheny Rabeh R, El Taweel Ahmed A, Kutkat Omnia O et al.

Spillover of influenza A(H5N1) virus to cattle in the United States sparked global concern. We investigated whether endemic avian influenza viruses are potentially spilling over into domestic livestock in Egypt. We detected influenza H9N2 antibodies in 2.5% and H5N1 antibodies in 2.9%-4.5% of tested animals. Additional surveillance will elucidate host infection dynamics.

PMID 43052695
阅读全文 →
PubMedAJE advances : research in epidemiology2026-11-19

A new surveillance landscape for seasonal influenza? Comparing lab-confirmed influenza hospitalizations with other syndromic and surveillance data sources for the state of California.

White Lauren A LA, Sun Monica M, Burnor Elisabeth E, Murray Erin L EL et al.

During the COVID-19 pandemic, US federal hospitalization surveillance systems provided a new data source for lab-confirmed influenza hospital admissions; these data were important for monitoring hospital capacity for combined respiratory virus pathogen burden and served as a new forecasting target for seasonal influenza forecasting efforts. For influenza surveillance in the state of California, from February 2, 2022 through May 31, 2025, we explored: (1) how lab-confirmed hospital admissions correlated with other syndromic and sentinel surveillance data; (2) which signals could serve as potential leading signals relative to hospital admissions; and (3) how these relationships varied across respiratory virus seasons and geography. Despite varying across seasons and regions, influenza surveillance data sources in California were strongly correlated with laboratory-confirmed influenza hospitalizations (Spearman's P ≥ 0.8). These correlations generally strengthened through time from the 2021-2022 season to the most recent 2024-2025 season, especially for death, influenza-like illness, wastewater, and clinical lab data. Electronic laboratory reporting was the only data source to provide consistent leads of 1-2 weeks relative to the admissions signal across all four seasons (Spearman's P ≥ 0.89). Understanding the relationship between different data sources will improve situational awareness and help inform future estimates of influenza burden.

PMID 43053790
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多influenza vaccine